"O Grupo Oncoclínicas é um dos maiores e mais respeitados grupos de oncologia, hematologia e radioterapia da América Latina. Hoje, contamos com 67 unidades em 11 dos principais estados brasileiros, com especialistas nas áreas de oncologia, radioterapia, hematologia e transplante de medula óssea, equipes multidisciplinares, cuidados complementares e o que há de mais avançado em assistência integrada e tratamento oncológico individualizado. Acolhimento, empatia, respeito e confiança são as bases de atuação que permeiam todas as nossas unidades, criando uma identidade única de atendimento, sempre pautado na excelência, com foco na segurança e na qualidade de vida do paciente."

During the past decade, Centro Paulista de Oncologia conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro Paulista de Oncologia" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Janssen-Cilag Ltd." with 1 trials as a collaborator and "Oncoclínicas" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Centro Paulista de Oncologia" are "Carcinoma, Non-Small-Cell Lung" (1 trials), "Medullary Thyroid Cancer" (1 trials), "Non-Small Cell Lung Cancer" (1 trials), "Prostate Cancer" (1 trials) and "Prostatic Neoplasms, Castration-Resistant" (1 trials). Many other conditions were trialed in "Centro Paulista de Oncologia" in a lesser frequency.

Most popular intervention types in "Centro Paulista de Oncologia" are "Drug" (5 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Selpercatinib" (3 trials), "Atezolizumab" (1 trials), "Cabozantinib" (1 trials), "Carboplatin" (1 trials) and "Cisplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centro Paulista de Oncologia" are 6 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Centro Paulista de Oncologia". undefined are not yet recruiting, 5 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Centro Paulista de Oncologia, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Centro Paulista de Oncologia, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".